Skip to Main Content
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Press Release: Miller-Meeks, Matsui, and Auchincloss Introduce Bipartisan Bill to Lower Prescription Drug Costs for Seniors

None

Dr. Miller-Meeks leads bipartisan efforts to enhance Medicare beneficiaries' access to affordable prescription drugs.

Quiver AI Summary

Bipartisan effort to reduce drug costs: Dr. Mariannette Miller-Meeks, along with Congresswoman Doris Matsui and Congressman Jake Auchincloss, is spearheading bipartisan legislation aimed at making prescription drugs more affordable for Medicare beneficiaries. The initiative seeks to lower costs and enhance access to generic and biosimilar medications.

Key provisions of the legislation: The proposed "Ensuring Access to Lower-Cost Medicines for Seniors Act" would encourage Medicare Part D plans to prioritize lower-cost generic options over more expensive brand-name drugs. This is intended to alleviate financial burdens on seniors.

Support from stakeholders: The bill has garnered support from organizations such as the Association for Accessible Medicines, emphasizing its focus on increasing transparency and fairness in the healthcare system while reducing out-of-pocket expenses for seniors.

Disclaimer: This is an AI-generated summary of a press release. The model used to summarize this release may make mistakes. See the full release here.

Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.

🏛️ Receive Alerts on Congress
Sign Up

Mariannette Miller-Meeks Fundraising

Mariannette Miller-Meeks Fundraising

Mariannette Miller-Meeks recently disclosed $722.4K of fundraising in a Q4 FEC disclosure filed on January 31st, 2026. This was the 103rd most from all Q4 reports we have seen this year. 61.2% came from individual donors.

Miller-Meeks disclosed $386.6K of spending. This was the 164th most from all Q4 reports we have seen from politicians so far this year.

Miller-Meeks disclosed $3.4M of cash on hand at the end of the filing period. This was the 104th most from all Q4 reports we have seen this year.

You can see the disclosure here, or track Mariannette Miller-Meeks's fundraising on Quiver Quantitative.

Mariannette Miller-Meeks Net Worth

Quiver Quantitative estimates that Mariannette Miller-Meeks is worth $1.8M, as of March 31st, 2026. This is the 263rd highest net worth in Congress, per our live estimates.

Miller-Meeks has approximately $0 invested in publicly traded assets which Quiver is able to track live.

You can track Mariannette Miller-Meeks's net worth on Quiver Quantitative's politician page for Miller-Meeks.

Mariannette Miller-Meeks Bill Proposals

Here are some bills which have recently been proposed by Mariannette Miller-Meeks:

  • H.R.8115: Precision Brain Health Research Act of 2026
  • H.R.8057: To amend title 38, United States Code, to modify the rate of pay for care or services provided under the Community Care Program of the Department of Veterans Affairs based on the location at which such care or services were provided, and for other purposes.
  • H.R.7550: Permanent Tax Relief for Seniors Act
  • H.R.7266: Rural and Municipal Utility Cybersecurity Act
  • H.R.7141: Affordable Housing Guarantee Act
  • H.R.7112: Veterans’ Bill of Rights Act of 2026

You can track bills proposed by Mariannette Miller-Meeks on Quiver Quantitative's politician page for Miller-Meeks.

2026 Iowa's 1st Congressional District Election

There has been approximately $39,839,471 of spending in Iowa's 1st congressional district elections over the last two years, per our estimates.

Approximately $24,448,940 of this has been from outside spending by PACs and Super PACs. Some of the groups who are spending money in this race include:

The rating for this race is currently "Toss Up".

You can track this election on our matchup page for the 2026 Iowa's 1st congressional district election.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles